Viridian therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4)

Waltham, mass.--(business wire)--viridian therapeutics, inc. (nasdaq: vrdn) (the “company” or “viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the compensation committee of the company's board of directors approved the grant of non-qualified stock options to purchase an aggregate of 450,000 shares of the company's common stock to.
NDAQ Ratings Summary
NDAQ Quant Ranking